国际标准期刊号: 2278-0238

国际药学与生命科学研究与发展杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Applications of Quality by Design (QbD) in formulation development

Devendra Ridhurkar

The main objective of pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the intended performance of the product. Pharmaceutical industry realized that Quality by Design (QbD) principles, when implemented, lead to a successful product development, subsequent prompt regulatory approval, reduce exhaustive validation burden, and    significantly reduce postapproval changes and also helps to build a quality in all pharmaceutical products. Hence the application of QbD in pharmaceutical product development is now a thrust area for the regulatory authorities and the pharmaceutical industry. International Conference on Harmonization and United States Food and Drug Administration (USFDA) emphasized the principles and applications of QbD in pharmaceutical development in their guidance for the industry. Target product quality profile, critical quality attributes, risk assessments, design space, control strategy, product lifecycle management, and continual improvement are the key elements of QbD. Throughout designing and development of a product with QbD, it is essential to define desire product performance profile Target product profile (TPP), Target product Quality profile(TPQP) and identify Critical quality attributed (CQA) leads to recognize the impact of raw material,Critical material attributes (CMA), Critical process parameter (CPP), on the CQA’s and identification and source of variability.